<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1822">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04381364</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02183</org_study_id>
    <nct_id>NCT04381364</nct_id>
  </id_info>
  <brief_title>Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)</brief_title>
  <acronym>HALT</acronym>
  <official_title>Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ola Blennow, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danderyd Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centrallasarettet Västerås</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St Goran's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized open label clinical trial carried out at study centers in Sweden, including
      Karolinska University Hospital, S:t Göran Hospital, Danderyd Hospital and Västmanlands
      Hospital. Patients with COVID-19 who are hospitalized with oxygen therapy are eligible for
      inclusion. Subjects are randomized to 14 days of inhalation with ciclesonide 360 µg twice
      daily or to standard of care. Primary outcome is duration of received supplemental oxygen
      therapy. Key secondary outcome is a composite outcome of death and received invasive
      mechanical ventilation within 30 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This multicenter study is an open-labelled, randomized clinical trial for 1:1 ratio of ciclesonide or control arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of received supplemental oxygen therapy</measure>
    <time_frame>30 days after study inclusion</time_frame>
    <description>Time (in days) of received supplemental oxygen therapy (defined as being alive and discharged from hospital to home or at least 48 h of not receiving oxygen therapy during hospitalization).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Invasive mechanical ventilation or all-cause death (key secondary outcome)</measure>
    <time_frame>30 days after study inclusion</time_frame>
    <description>Rate of and time to (in days) received invasive mechanical ventilation or all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>30 days after study inclusion</time_frame>
    <description>Rate of and time to (in days) death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive mechanical ventilation</measure>
    <time_frame>30 days after study inclusion</time_frame>
    <description>Rate of and time to (in days) received invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remaining dyspnea symptoms</measure>
    <time_frame>30-35 days and 5-7 months after inclusion</time_frame>
    <description>Level of remaining dyspnea symptoms according to the Modified Medical Research Council Dyspnea Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">446</enrollment>
  <condition>Covid-19</condition>
  <condition>Pneumonia, Viral</condition>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>Medical treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with ciclesonide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard Medical Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide Inhalation Aerosol</intervention_name>
    <description>Ciclesonide 320 µg twice daily for 14 days.</description>
    <arm_group_label>Medical treatment</arm_group_label>
    <other_name>Alvesco</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 or older who are willing and able to provide written informed consent.

          2. Laboratory-confirmed (PCR-positive) SARS-CoV-2 infection.

          3. Receiving supplemental oxygen therapy with start &lt;48 hours before inclusion.

          4. Negative pregnancy test (women in fertile age).

          5. Agreeing to take highly effective contraceptive measures according to Clinical Trial
             Facilitation Group criteria during the duration of treatment plus 7 days (women in
             fertile age).

        Exclusion Criteria:

          1. Pregnant or breastfeeding women.

          2. History of hypersensitivity to ciclesonide or other substances included in the
             treatment.

          3. Ongoing use of corticosteroids, ketokonazol, itrakonazol, ritonavir or nelfinavir.

          4. Receiving &gt;8 l oxygen/min or &gt;50 % oxygen with nasal high flow therapy.

          5. Ongoing or planned palliative care or an expected survival of less than 72 h.

          6. Expected admission to intensive care unit within 48 h.

          7. Active or inactive pulmonary tuberculosis.

          8. Severe liver failure (Child-Pugh C)

          9. Pulmonary arterial hypertension (PAH) or fibrosis.

         10. Cognitive or physical impairment or insufficient language skills which precludes
             understanding of information given about the study.

         11. Participation in a clinical trial within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel P Andersson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ola Blennow, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capio S:t Görans Hospital and Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Brodin, MD</last_name>
    <phone>+46736313527</phone>
    <email>daniel.brodin@capiostgoran.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel P Andersson, MD, PhD</last_name>
    <phone>+46704490004</phone>
    <email>daniel.p.andersson@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danderyd Hospital</name>
      <address>
        <city>Danderyd</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Westerlund, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capio S:t Görans Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Brodin, MD</last_name>
      <email>daniel.brodin@capiostgoran.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel P Andersson, MD, PhD</last_name>
      <email>daniel.p.andersson@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visby Hospital</name>
      <address>
        <city>Visby</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas Lindell, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Västmanland County Hospital Västerås</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Krifors, MD</last_name>
      <email>anders.krifors@regionvastmanland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Athlin, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St Goran's Hospital</investigator_affiliation>
    <investigator_full_name>Ola Blennow, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Corona virus</keyword>
  <keyword>Covid-19</keyword>
  <keyword>Sars-CoV2</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Human</keyword>
  <keyword>Intervention study</keyword>
  <keyword>Corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

